雷替曲塞同步放疗治疗晚期食管癌的效果观察

Observation on the therapeutic efficacy of concurrent radiotherapy with raltitrexed in the treatment of advanced esophageal cancer

目的 探讨晚期食管癌患者给予雷替曲塞同步放疗治疗的效果。方法 选取2020年8月至2021年9月新泰市人民医院收治的74例晚期食管癌患者作为研究对象,采用随机数表法将其分为观察组(n=37)与对照组(n=37)。对照组采用放疗治疗,观察组在对照组基础上加用雷替曲塞治疗。比较两组患者的近期疗效、肿瘤标志物及不良反应。结果 观察组患者客观缓解率(ORR)、疾病控制率(DCR)均高于对照组,差异有统计学意义(P <0.05);两组患者治疗后癌胚抗原(CEA)、鳞状上皮细胞癌相关抗原(SCC)水平低于本组治疗前,观察组患者治疗后CEA、SCC水平低于对照组,差异有统计学意义(P <0.05);两组患者不良反应发生率比较,差异无统计学意义(P> 0.05)。结论 晚期食管癌患者给予雷替曲塞同步放疗治疗,能够提高近期疗效,改善患者肿瘤标志物水平,且未增加不良反应。

Objective To explore the efficacy of concurrent radiotherapy with raltitrexed in patients with advanced esophageal cancer. Methods A total of 74 advanced esophageal cancer patients who were admitted in the People’s Hospital of Xin Tai City from August 2020 to September 2021 were selected as the research objects, and by the random number table method, they were divided into the observation group(n=37) and the control group(n=37). Radiotherapy was treated in the control group, raltitrexed on the basis of the control group was treated in the observation group. The short-term therapeutic efficacy, tumor markers and adverse reactions(ARs) in both groups were compared. Results Compared with the control group, the objective remission rate(ORR) and disease control rate(DCR) of patients in the observation group were all higher(P < 0.05). The levels of carcinoembryonic antigen(CEA) and squamous cell carcinoma antigen(SCC) associated antigen in both groups after treatment were lower than those before treatment, and compared with the control group, the levels of CEA and SCC of patients in the observation group after treatment were lower(P < 0.05). In the incidence of ARs, there was no statistically significant difference between the two groups of patients(P > 0.05). Conclusion Concurrent radiotherapy with raltitrexed in patients with advanced esophageal cancer can enhance the shortterm therapeutic efficacy, improve the level of patient’s tumor markers, and will not increase ARs.